ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2021
Serum ceramide levels are altered in multiple sclerosis.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Differential Ceramide Metabolism in Autogenous and Reactive Obsessions: A Biomarker Perspective in OCD.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Lipidomic perspectives on the role of lactosylceramides in inflammation and disease: A narrative review.Expert reviews in molecular medicine · 2026Review
- Article
- A potential of serum anti-C1P IgG antibodies as biomarkers in differential diagnosis of relapsing-remitting multiple sclerosis.Scientific reports · 2026Article
- Presence and relevance of serum anti-C1P IgG antibodies in relapsing-remitting multiple sclerosis.Research square · 2025Article
- The Serum Lipid Profile of Relapsing Multiple Sclerosis Differs Reproducibly From Healthy Controls.Journal of neurochemistry · 2025Article
- Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.International journal of molecular sciences · 2025Review
- Evaluating metabolome-wide causal effects on risk for psychiatric and neurodegenerative disorders.BMC medicine · 2025Article
- Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis.Metabolites · 2024Review
- Identification ofCells · 2024Article
- Serum lipidome associates with neuroimaging features in patients with traumatic brain injury.iScience · 2024Article
- Metabolomics of Multiple Sclerosis Lesions Demonstrates Lipid Changes Linked to Alterations in Transcriptomics-Based Cellular Profiles.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Plasma Lipidomic Profiling Using Mass Spectrometry for Multiple Sclerosis Diagnosis and Disease Activity Stratification (LipidMS).International journal of molecular sciences · 2024Article
- Proteomic and metabolomic profiling of plasma uncovers immune responses in patients with Long COVID-19.Frontiers in microbiology · 2024Article
- Article
- CDP-choline to promote remyelination in multiple sclerosis: the need for a clinical trial.Neural regeneration research · 2023Review
- Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.Lipids in health and disease · 2023Article
- Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Seasonal Changes in Serum Metabolites in Multiple Sclerosis Relapse.International journal of molecular sciences · 2023Article
- Untargeted analysis in post-COVID-19 patients reveals dysregulated lipid pathways two years after recovery.Frontiers in molecular biosciences · 2023Article
Corrections and comments
- Commented on by
- Commented on byResponse to-2022
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSphingolipids are myelin components and inflammatory signaling intermediates. Sphingolipid metabolism may be altered in people with multiple sclerosis (PwMS), but existing studies are limited by small sample sizes.
objectivesTo compare the levels of serum ceramides between PwMS and healthy controls (HCs) and to determine whether ceramide levels correlate with disability status, as well as optical coherence tomography (OCT)-derived rates of retinal layer atrophy.
methodsWe performed targeted lipidomics analyses for 45 ceramides in PwMS (
resultsSeveral ceramides, including hexosylceramides, lactosylceramides, and dihydroceramides, were altered in PwMS compared with HCs. Higher levels of Cer16:0 were associated with higher odds of EDSS worsening at 5 years in univariable (odds ratio (OR) = 3.84, 95% confidence interval (CI) = 1.41-10.43) and multivariable analyses accounting for age, sex, and race (OR = 2.97, 95% CI = 1.03-8.59). Each 1 ng/mL higher concentration of Hex-Cer22:0 and DH-HexCer22:0 was associated with accelerated rates (μm/year) of ganglion cell + inner plexiform layer (-0.138 ± 0.053,
conclusionCeramide levels are altered in PwMS and may be associated with retinal neurodegeneration and physical disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.